FDA Advisers to Review Galleri Multi-Cancer Blood Test

An independent advisory panel is set to consider whether to recommend FDA approval of Grail’s Galleri blood test. The company says the test can detect signals associated with up to 50 cancers, NPR reports. The advisory review is a pending step and does not itself mean the test has received FDA approval.